Page 2480 - Williams Hematology ( PDFDrive )

2451
2450 Index Index 2451

Immunoglobulin (Ig) A naturally occurring antibodies, 2347 synthesis, 1171
in α-heavy-chain disease, 1806 in newborn, 106 in Waldenström macroglobulinemia, 1714,
in ataxia-telangiectasia, 1226 structure and function, 1160–1161, 1160f, 1788–1791, 1789t
blood group activity and, 2347 1160t, 1161t Immunoglobulin (Ig) M+ B lymphocytes,
in class switching, 1168 Immunoglobulin (Ig) G+ B lymphocytes, 863 863
in complement system, 290 Immunoglobulin (Ig) G monoclonal Immunoglobulin (Ig) M monoclonal
in γ-heavy-chain disease, 1804 gammopathy, 1722, 1722t, 1725, gammopathy, 1722, 1722t, 1725.
immune antibodies, 2348 1727, 1741. See also Essential See also Essential monoclonal
levels in newborns, 108 monoclonal gammopathy gammopathy
in mycosis fungoides, 1680 Immunoglobulin heavy-chain (IGH) genes Immunoglobulin (Ig) M myeloma, 1760
in myeloma, 1714 in chronic lymphocytic leukemia, 1531, Immunoglobulin (Ig) superfamily, 66, 67t,
naturally occurring antibodies, 2347 1531t, 1532t, 1542 282t
selective deficiency, 1214t, 1216, 2375 in myeloma, 1734–1735, 1735f, 1736t Immunological synapse, 1185–1186
structure and function, 1160t, 1161–1162, structure, 1163–1164, 1164f, 1167f Immunologic theory of aging, 131
1161t Immunoglobulin light-chain (AL) Immunomodulation, of macrophage
Immunoglobulin (Ig)-α. See CD79a (Ig-α) amyloidosis phenotype, 1084, 1085f
Immunoglobulin (Ig) A monoclonal chromosomal abnormalities, 1712, 1774 Immunomodulatory drugs, 333–335, 333f.
gammopathy, 1722, 1722t, 1725, clinical features, 1744–1745, 1760, 1774– See also specific drugs
1727, 1741. See also Essential 1775, 1774f, 1775f, 1775t for myeloma, 1754
monoclonal gammopathy cardiac, 1777–1779, 1778f for sickle cell disease, 774t, 775
Immunoglobulin (Ig) A nephropathy, 1161 hepatic, 1779 Immunoosseous dysplasias
Immunoglobulin (Ig)-β (CD79b), 1162, 1162f neurologic, 1779 cartilage hair hypoplasia, 993, 1226
Immunoglobulin (Ig) D renal, 1776–1777 Schimke syndrome, 1226
pre-B cells and, 1168 course and prognosis, 1781–1782 Immunophenotyping, 35
structure and function, 1160t, 1161t, 1162 definition and history, 1773 of abnormal population, 37–38
Immunoglobulin (Ig) D+, 863 diagnosis, 1760, 1779t methodology, 36–37
Immunoglobulin (Ig) E differential diagnosis, 1775–1776, 1776f of mycosis fungoides, 1682, 1682f
in ataxia-telangiectasia, 1226 epidemiology, 1773 Immunoproliferative small intestinal disease
in chronic inflammation, 291 etiology and pathogenesis, 1781–1782 (IPSID), 1663, 1665, 1808, 1809
excess levels. See Hyperimmunoglobulin E laboratory features, 1775 Immunoreceptor tyrosine-based activation
syndrome (HIES) treatment, 1760–1761, 1779–1781 motifs (ITAMs)
in mycosis fungoides, 1680 Immunoglobulin (Ig) light chains, 1159 Fc receptors and, 1053f
structure and function, 1160t, 1161t, allotypes, 1170–1171 glycoprotein VI and, 1869
1162–1163 in amyloidosis, 1773–1774. See also immunoglobulins and, 1162f, 1163
Immunoglobulin (Ig) E-associated responses, Immunoglobulin light-chain (AL) Src binding and, 1016
932, 969, 971 amyloidosis T-cell receptors and, 1176f, 1178
Immunoglobulin (Ig) family cell adhesion in essential monoclonal gammopathy, Immunoreceptor tyrosine-based switch motif
molecules, 1858–1859t, 1868–1870 1708, 1721 (ITSM), 1868
Immunoglobulin (Ig) G gene complexes, 1165f, 1167f Immunoreceptor tyrosine inhibitory motif
atherosclerosis and, 2287 laboratory evaluation, 1714 (ITIM), 1184, 1190, 1868, 1884
in autoimmune hemolytic anemia, 823, in myeloma, 1714, 1741, 1742f Immunosuppressive therapy
834, 834f, 835 surrogate λ, 1168 for acquired hemophilia A, 2186
blood group activity and, 2343 vasculopathy, 2099 for aplastic anemia, 523–526, 524t, 525t
in complement system, 289–290, 289f Immunoglobulin (Ig) M for autoimmune hemolytic anemia, 839
cryoglobulinemia and, 2097 atherosclerosis and, 2287 lymphoma and, 1574
direct antiglobulin test reaction patterns, in autoimmune hemolytic anemia, 2348 for myelodysplastic syndromes, 1359
834t blood group activity and, 2343, 2347 for pure red cell aplasia, 544
eosinophil receptors for, 953 in complement system, 289, 289f Immunotherapy
human body content of, 1171 excess levels. See Hyperimmunoglobulin for acute myelogenous leukemia, 1404
immune antibodies, 2348 M syndromes dendritic cells in, 310
immune thrombocytopenia and, 2000 immune antibodies, 2348 for hemophagocytic lymphohistiocytosis,
infusions. See Intravenous naturally occurring antibodies, 2347 1115
immunoglobulin (IVIg) pre-B cells and, 1168 natural killer cells in, 1192
levels in newborns, 108 production, 1151 Immunothrombosis, 1940–1941, 1941f
major subclasses, 1161t structure and function, 1160t, 1161t, 1162, Immunotoxins, 345–346
in myeloma, 1714 1162f Impairment of consciousness, history of, 5

Kaushansky_index_p2393-2506.indd 2451 9/21/15 3:22 PM